Clinical efficacy of S-1 in pretreated metastatic breast cancer patients

Tadahiko Shien, Chikako Shimizu, Sadako Akashi-Tanaka, Kan Yonemori, Tsutomu Kohno, Takashi Hojo, Masashi Ando, Noriyuki Katsumata, Takayuki Kinoshita, Yasuhiro Fujiwara

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: S-1, an oral fluoropyrimidine carbamate, is an active and well-tolerated agent against solid cancer. However, the clinical efficacy of S-1 in patients with metastatic breast cancer has not been determined. Methods: We retrospectively evaluated the efficacy of S-1 and identified its adverse effects in patients with metastatic breast cancer who had failed to respond to prior chemotherapy regimens. All the patients were treated at the National Cancer Center Hospital and received S-1 twice daily at a dose of 80 mg/m2 for 4 weeks, followed by a 2-week rest interval. Results: Between 2003 and 2007, 37 women with metastatic breast cancer received S-1 as a third line or greater chemotherapy regimen. All the patients had been previously treated with both anthracyclines and taxanes prior to S-1 chemotherapy. The median order of S-1 administration was as a fifth-line treatment, and 23 patients (62%) received S-1 as their final anticancer drug. One (3%) partial response and two (5%) stable diseases were observed. The median time to progression (TTP) was 84 days. Grade 2 adverse events, such as diarrhea, stomatitis and neutropenia occurred in 5 (16%), 1 (3%) and 1 (3%) patients, respectively. Conclusions: S-1 was safety administered to heavily treated metastatic breast cancer patients with limited efficacy. Further evaluation of S-1 is necessary to elucidate its clinical role in breast cancer treatment.

Original languageEnglish
Pages (from-to)172-175
Number of pages4
JournalJapanese journal of clinical oncology
Volume38
Issue number3
DOIs
Publication statusPublished - Mar 2008

Keywords

  • Cancer
  • Chemotherapy
  • Metastatic breast
  • S-1

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical efficacy of S-1 in pretreated metastatic breast cancer patients'. Together they form a unique fingerprint.

  • Cite this

    Shien, T., Shimizu, C., Akashi-Tanaka, S., Yonemori, K., Kohno, T., Hojo, T., Ando, M., Katsumata, N., Kinoshita, T., & Fujiwara, Y. (2008). Clinical efficacy of S-1 in pretreated metastatic breast cancer patients. Japanese journal of clinical oncology, 38(3), 172-175. https://doi.org/10.1093/jjco/hyn001